DeCure for Maxillary Sinus Adenoid Cystic Carcinoma
DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for Maxillary Sinus Adenoid Cystic Carcinoma — screening already-approved drugs against its 6-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleMaxillary Sinus Adenoid Cystic Carcinoma maps to a 6-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for maxillary sinus adenoid cystic carcinoma is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
CREB binding lysine acetyltransferase (CREBBP) — CREBBP is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 1vudrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 9H0K · 1.75 Å · ligand propionyl Coenzyme A (1VU). Experimental structure, not a prediction.
What the evidence adds up to
A prospective pilot study from 1985 treated sixty patients with paranasal sinus cancer (including maxillary sinus) with surgery, low-dose irradiation, and a topically applied cytostatic drug. The local control rate was 65%. The actuarial 2-year and 5-year survival rates were 76% and 65%, respectively. For squamous cell carcinoma and undifferentiated carcinoma of the maxillary sinus specifically, the actuarial 5-year survival rate was 52%. The study did not report separate survival data for adenoid cystic carcinoma of the maxillary sinus.
Two case reports from 2024 describe adenoid cystic carcinoma of the maxillary sinus in a 73-year-old woman and a 53-year-old woman. Both presented with nasal obstruction; the second also had a hard palatal mass. The first patient was referred for radiotherapy after biopsy. The second underwent mass excision followed by radiation therapy. The authors note that this cancer is often diagnosed at an advanced stage because of its slow growth and local regional spread, making diagnosis and therapeutic management particularly challenging. No survival or response data are given for these two patients.
A 1992 case report describes a 70-year-old man with adenosquamous carcinoma of the maxillary sinus, a different histology. He was treated with radiotherapy, chemotherapy, and radical surgery. The authors state that the prognosis for adenosquamous carcinoma is extremely poor, similar to undifferentiated carcinoma, and that radiation and chemotherapy have little ability to cure this tumor. They advocate for aggressive radical surgery. This report does not address adenoid cystic carcinoma.
What is still missing for adenoid cystic carcinoma of the maxillary sinus is any prospective trial data, any controlled comparison of treatment regimens, and any reliable survival or response rates specific to this histology at this site. The available evidence consists of small case series and older studies that lump multiple sinus cancer types together. No drug has been tested in a dedicated trial for this condition, and no patient stratification strategy has been validated.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Cancer · 1985 · 84 citations
Carcinoma of the paranasal sinuses results of a prospective pilot study
AbstractSixty patients with paranasal sinus cancer were treated from January 1976 until July 1981 according to a standard protocol in which surgery is combined with a low dose of irradiation and a topically applied cytostatic drug. The local control rate was 65%. Mutilation was clearly reduced. The actuarial 2-year and 5-year survival rate was 76% and 65%, respectively. The actuarial 5-year survival rate for squamous cell carcinoma and undifferentiated carcinoma of the maxillary sinus was 52%. For adenocarcinoma of the ethmoid sinus the actuarial 5-year survival rate was 100%. The results of this prospective pilot study suggest that it may be possible to achieve better results with less aggressive treatment.
Pan African Medical Journal · 2024 · 0 citations · open access
Adenoid cystic carcinoma of maxillary sinus: report of two cases
AbstractAdenoid cystic carcinoma infrequently affects paranasal sinuses. It's a slowly progressing, aggressive cancer with a tendency to invade nerves. The research underscores the significance of prompt diagnosis and effective management of adenoid cystic carcinoma. Two cases of adenoid cystic carcinoma of the maxillary sinus are presented. The first, a 73-year-old woman, presented with right nasal obstruction. The second, a 53-year-old woman, presented with a hard palatal mass and right nasal obstruction. The biopsy confirmed adenoid cystic carcinoma in the first patient. Given the extent of the tumor, she was referred to radiotherapy to complement the therapeutic treatment. The second patient underwent mass excision, also confirmed to be adenoid cystic carcinoma, followed by radiation therapy. Adenoid cystic carcinoma of the maxillary sinus is often diagnosed at an advanced stage due to its slow growth and local regional spread, making its diagnosis and therapeutic management particularly challenging.
Practica Oto-Rhino-Laryngologica · 1992 · 0 citations · open access
Adenosquamous Carcinoma of the Maxillary Sinus; A Case Report.
AbstractA case of adenosquamous carcinoma of the maxillary sinus is reported. A 70-year-old man with adenosquamous carcinoma in the maxillary sinus was treated with radiotherapy, chemotherapy and radical surgery. Adenosquamous carcinoma is very rare in the paranasal sinuses. The prognosis is extremetly poor, similar to that for undifferentiated carcinoma. Radiation therapy and chemotherapy evidently have little ability to cure this tumor. We believe that the treatment of adenosquamous carcinoma requires aggressiveand radical surgery.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
